CEO Exit Adds To Iovance Woes After Cell Therapy Setback

Filing Set Back Until 2022

 
• By Andrew McConaghie
  
Iovance Philadelphia Navy Yard rendering
The company's GMP cell therapy manufacturing facility in Navy Yard, Philadelphia is expected to be completed this year. • Source: DIGSAU
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip